ALTS1C1 Syngeneic Model Service for Glioblastoma

The ALTS1C1 syngeneic model is a surgically invasive, immunocompetent glioblastoma platform that implants SV40-transformed murine astrocytoma cells into the brains of syngeneic C57BL/6 mice, recapitulating the infiltrative growth, necrosis, and immunosuppressive microenvironment of human high-grade glioma. Alfa Cytology delivers this model as a complete preclinical service — authenticated cell banking, stereotactic intracranial or flank implantation, longitudinal bioluminescence and MRI monitoring, temozolomide-referenced efficacy testing, and comprehensive terminal histopathology — giving sponsors a translationally faithful CNS tumor system without investing in neurosurgical infrastructure, intracranial imaging, or specialized survival analysis capability in-house.

Overview of ALTS1C1 Syngeneic Model for Glioblastoma

ALTS1C1 is a murine anaplastic astrocytoma line created to capture the defining tragedy of high-grade glioma: not the primary mass, but the invasion. Established by Wang and colleagues in 2012 through in vitro transformation of astrocytes with SV40 large T antigen, the line was deliberately engineered to model infiltrative disease, and its orthotopic tumors recapitulate the canonical histopathology of human glioblastoma — increased cellularity, pronounced cellular pleomorphism, geographic necrosis, active mitosis, and extensive invasion of tumor cells into adjacent brain parenchyma along white-matter tracts. Two molecular signatures anchor the model's biology. It expresses stromal cell-derived factor-1 (SDF-1/CXCL12) at high levels both in vitro and in vivo, and its tumors carry elevated microvascular density; SDF-1 knockdown converts the phenotype dramatically, producing tumors with well-defined regular borders, no infiltration tracts, reduced vascular density, expanded hypoxic areas, and redistribution of F4/80-positive tumor-associated macrophages away from hypoxic regions — an elegant demonstration that a single chemokine governs the invasive-vascular-immune axis of this tumor.

Fig 1. Vascular heterogeneity between tumor edge and core in the ALTS1C1 orthotopic glioblastoma model — CD31 immunostaining and dextran perfusion reveal higher microvascular density but lower vessel leakage at the invasive tumor edge. (Lin, Chiu-Min, et al., 2019)

Because ALTS1C1 is syngeneic to C57BL/6, intracranial implantation in immunocompetent hosts preserves the full tumor-immune dialogue that human xenografts necessarily forfeit, and the model has become a proving ground for glioblastoma immunotherapy. Subcutaneous flank implants express PD-L1 and have hosted photothermal-immunotherapy studies combining near-infrared irradiation with anti-PD-L1-targeted nanoparticles and TLR7/8 agonists, while intracranial co-implantation with microglial BV2 cells revealed a striking immune dependency: a 50% BV2 admixture completely represses tumor growth, quadrupling CD8 T-cell infiltration and doubling PD-1 expression, with rechallenge experiments confirming systemic antitumor immunity. Orthotopically, median survival of untreated C57BL/6 hosts runs roughly four weeks, a window that accommodates standard temozolomide benchmarking — reference compounds extending survival from about 26 to 31 days in published studies — as well as novel agents, sigma-receptor ligands, and nanomedicine formats. The luciferase-tagged ALTS1C1-luc derivative enables quantitative bioluminescence tracking of intracranial tumor burden on IVIS-class imagers, while MRI provides anatomical confirmation, making the platform a complete, immunologically intact system for preclinical glioblastoma research.

Cell Line Information: ALTS1C1

ALTS1C1 (Cellosaurus CVCL_WH52) is a murine anaplastic astrocytoma line established in 2012 through SV40 large T antigen transformation of astrocytes, as reported by Wang and colleagues. The luciferase-tagged derivative ALTS1C1-luc is generated by stable reporter transduction and is used for quantitative bioluminescence tracking of intracranial and subcutaneous disease. Core characteristics are compiled below.

Our Services

Engaging Alfa Cytology for the ALTS1C1 syngeneic model places the entire intracranial workflow under one accountable team: authenticated, low-passage cell banks are maintained under BSL-2 discipline, syngeneic C57BL/6 hosts are prepared and acclimated, tumor cells are implanted stereotactically into the striatum — or subcutaneously where study design prefers — by neurosurgeons experienced with the technique, intracranial burden is followed by scheduled bioluminescence imaging and MRI, and treatment arms from temozolomide benchmarks to checkpoint combinations and nanomedicine formats are executed through survival endpoints and terminal brain histopathology, all under IACUC-compliant conditions and returned as an audit-ready data package.

Workflow of ALTS1C1 Syngeneic Model Construction

ALTS1C1 studies divide into the definitive stereotactic intracranial format — where survival is the primary endpoint — and the practical subcutaneous format used for immunotherapy screening; both demand disciplined cell preparation and aseptic neurosurgical technique. A standard program proceeds as follows.

1. Cell preparation and quality control: ALTS1C1 or ALTS1C1-luc cells are expanded at low passage, confirmed mycoplasma-free, and luciferase activity validated in vitro; single-cell suspensions of defined concentration are prepared fresh immediately before implantation.
2. Host selection and acclimation: Male or female C57BL/6 mice, typically 6–10 weeks of age, are quarantined and acclimated in a specific-pathogen-free barrier facility, with cohorts size-matched to the survival-powered study design.
3. Stereotactic setup and craniotomy: Under isoflurane anesthesia with ophthalmic protection and body-temperature support, the head is fixed in a stereotactic frame, the scalp is disinfected and incised, and a small burr hole is drilled at the coordinate pair over the striatum.
4. Intracranial implantation: A Hamilton microsyringe is lowered to the striatal coordinates, and a small-volume cell suspension — on the order of 10⁵ cells in 2–5 μL — is infused slowly, typically at ~0.5 μL per minute, with a dwell time before withdrawal to prevent reflux along the needle track.
5. Recovery and perioperative care: The burr hole is sealed, the scalp is closed with sutures or clips, and mice recover on warming with analgesia and twice-daily neurological observation against predefined humane endpoints.
6. Engraftment verification and monitoring: For luciferase-tagged cohorts, bioluminescence imaging after intraperitoneal D-luciferin injection confirms intracranial take and tracks tumor burden, with T2-weighted MRI providing anatomical validation of lesion location and midline shift.
7. Randomization and treatment: Mice are randomized to arms at a defined post-implantation interval, and test articles, checkpoint inhibitors, radiotherapy, or nanomedicine formats are dosed per protocol, with body weight and neurological status scored at defined intervals.
8. Survival analysis and terminal histopathology: Kaplan–Meier survival is the primary endpoint, analyzed by log-rank test; brains of endpoint animals undergo H&E and immunohistochemistry (GFAP, CD31, F4/80, CD8, PD-1/PD-L1 panels) to characterize invasion, necrosis, angiogenesis, and immune infiltration, and all data are consolidated into the final report.

Fig 2. ALTS1C1 Syngeneic Model construction workflow.

Case Study-ALTS1C1 Syngeneic Model Development

Alfa Cytology has applied the ALTS1C1 syngeneic platform to preclinical programs spanning temozolomide-referenced efficacy studies, checkpoint and photothermal immunotherapy combinations, and tumor-microenvironment interventions in glioblastoma. In these engagements, longitudinal bioluminescence imaging quantified intracranial tumor burden while survival analysis with Kaplan–Meier methods served as the primary endpoint, and terminal brain histopathology with invasion and immune-marker panels completed the pharmacological assessment. Study parameters — implantation format, imaging cadence, randomization intervals, and endpoint criteria — are tailored to each program. Case materials can be shared under confidentiality agreements upon request.

Why Choose Alfa Cytology?

Intracranial syngeneic work is unforgiving: imprecise stereotaxy, inconsistent inocula, or shallow survival analysis quietly corrupt results. Alfa Cytology fields the neurosurgical, imaging, and statistical capabilities in-house, making the ALTS1C1 syngeneic model a dependable backbone for your glioblastoma program.

• Stereotactic neurosurgical expertise, with coordinate-level reproducibility and low perioperative loss.
• Dual-modality intracranial monitoring uniting quantitative bioluminescence with anatomical MRI.
• Genuine immunocompetent CNS biology, preserving the glioma-immune dialogue that xenografts forfeit.
• Validated SDF-1/CXCL12 and angiogenesis biology, supporting mechanism-informed study designs.
• Temozolomide-referenced benchmarking against published survival windows (~26-day control median).
• Survival-powered statistical rigor, with Kaplan–Meier and log-rank analysis as standard deliverables.
• IACUC-compliant, documentation-rich operations delivering audit-ready records throughout the study.

Contact Us

If your glioblastoma program needs an immunocompetent orthotopic platform, contact us today to discuss ALTS1C1 / ALTS1C1-luc study design, implantation format, imaging strategy, and survival endpoints with our scientific team. Reach out for a confidential consultation and project quotation — Alfa Cytology looks forward to advancing your next preclinical study.

For research use only. Not intended for any clinical use.